Vectura is a provider of innovative inhaled drug delivery services that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.
Vectura has thirteen key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.
For further information, please visit Vectura's website at www.vectura.com
Vectura has thirteen key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.
For further information, please visit Vectura's website at www.vectura.com
Location: United Kingdom, England, Chippenham
Employees: 201-500
Founded date: 1997
Investors 1
| Date | Name | Website |
| - | Life Scien... | lspvc.com |
Mentions in press and media 9
| Date | Title | Description |
| 26.09.2024 | Anora’s science-based emission reduction targets approved by the SBTi | Anora’s science-based emission reduction targets approved by the SBTi Thu, Sep 26, 2024 12:00 CET Report this content As part of its ambitious Sustainability Roadmap, Anora joined the Science Based Targets initiative (SBTi) in 2022, which i... |
| 11.09.2024 | Blossa 2024 – A mysterious whisky journey with a smoky flavor and notes of seaweed | Blossa 2024 – A mysterious whisky journey with a smoky flavor and notes of seaweed Wed, Sep 11, 2024 11:00 CET Report this content After a journey across this year's destination, Scotland, Blossa 24 is filled with smoke and Scottish mystiqu... |
| 20.08.2024 | Anora Group Plc’s Half-year Report January–June 2024: Comparable EBITDA improved in Q2 due to higher gross margin | Anora Group Plc’s Half-year Report January–June 2024: Comparable EBITDA improved in Q2 due to higher gross margin Tue, Aug 20, 2024 07:30 CET Report this content Anora Group Plc Half-year Report 20 August 2024 at 8:30 am EEST Anora Group Pl... |
| 09.08.2021 | Is being Stripe’s competitor now a badge of honor? | Happy Monday, Term Sheet readers. Finance reporter Anne Sraders here, filling in for Lucinda while she takes a well-deserved break. Paid Content Why marketers are benefitting from a scientific mindset From Optimizely Startups usually don’t ... |
| 09.08.2021 | Is being Stripe’s competitor now a badge of honor? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Happy Monday, Term Sheet readers. Finance reporter Anne Sraders here, filling in for Lucinda whil... |
| 12.07.2021 | In Didi’s crackdown, the battle for new oil is on | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. The founders of China’s largest ride-sharing operation had less than a week to revel in their new... |
| 10.06.2021 | VECTURA GROUP Vectura : announces completion of management buy-out of Lyon oral subsidiary, Skyepharma Production SAS Published10/06/2021 Read more | Published:10/06/2021 Vectura Group plc, an industry-leading specialist inhalation CDMO, today announces the successful completion of a management buy-out of its oral manufacturing subsidiary in Lyon, Skyepharma Production SAS. In 2019, Vect... |
| 21.04.2021 | VECTURA GROUP PLC Vectura : highlights update made by Hikma on launch of generic Advair Diskus® Published21/04/2021 Read more | Published:21/04/2021 Vectura Group highlights the announcement made today by Hikma Pharmaceuticals PLC regarding its launch of generic Advair Diskus®. Hikma Pharmaceuticals PLC today posted the following statement: 'Hikma Pharmaceuticals PL... |
| 22.09.2020 | VECTURA GROUP PLC Vectura : Status update on VR315 (US) | Published:22/09/2020 Vectura Group confirms the announcement made today by its partner Hikma Pharmaceuticals. Hikma has received a minor complete response letter (CRL) from the US Food and Drug Administration (FDA) in relation to its abbrev... |